Table 4. OR and 95% CI from conditional logistic regression of non-aggressive prostate cancer comparision of the 90th and 10th percentiles for serum metabolites (P<0.05) sorted by chemical class, sub-pathway, and P-valuea , b.
| Metabolite | Sub-pathway | OR | 95% CI | P-value | P-value for chemical class |
|---|---|---|---|---|---|
|
Amino acids and amino acids derivatives |
0.69 | ||||
| 2-Aminoadipate | Lysine metabolism | 0.63 | 0.41, 0.96 | 0.0311 | |
| Pipecolate | Lysine metabolism | 0.68 | 0.48, 0.97 | 0.0332 | |
| 3-Indoxyl sulfate | Tryptophan metabolism | 0.70 | 0.49, 1.00 | 0.0483 | |
|
Cofactors and vitamins |
0.18 | ||||
| Alpha-CEHC glucuronide | Tocopherol metabolism | 0.63 | 0.44, 0.90 | 0.0105 | |
| Gamma-tocopherol/beta-tocopherol | Tocopherol metabolism | 1.51 | 1.07, 2.14 | 0.0196 | |
| Alpha-CEHC sulfate | Tocopherol metabolism | 0.68 | 0.49, 0.95 | 0.0242 | |
| Alpha-tocopherol | Tocopherol metabolism | 0.66 | 0.45, 0.96 | 0.0278 | |
|
Lipids |
0.32 | ||||
| 1-Palmitoleoyl-2-linoleoyl-GPC (16:1/18:2) | Phospholipid metabolism | 0.58 | 0.40, 0.86 | 0.0060 | |
| 1-Palmitoyl-2-linolenoyl-GPC (16:0/18:3) | Phospholipid metabolism | 1.62 | 1.05, 2.49 | 0.0293 | |
| 1-Linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6) | Phospholipid metabolism | 1.50 | 1.04, 2.16 | 0.0303 | |
| Taurocholate | Primary bile acid metabolism | 0.60 | 0.40, 0.88 | 0.0094 | |
| Glycocholate | Primary bile acid metabolism | 0.69 | 0.49, 0.96 | 0.0272 | |
| 4-Androsten-3beta,17beta-diol monosulfate | Steroid | 0.62 | 0.43, 0.90 | 0.0117 | |
| 5Alpha-androstan-3alpha,17beta-diol monosulfate | Steroid | 0.61 | 0.40, 0.92 | 0.0187 | |
| Dehydroepiandrosterone sulfate | Steroid | 0.64 | 0.44, 0.93 | 0.0204 | |
| 17Alpha-hydroxypregnenolone sulfate | Steroid | 0.70 | 0.51, 0.97 | 0.0303 | |
| 4-Androsten-3beta,17beta-diol disulfate | Steroid | 0.72 | 0.52, 0.99 | 0.0431 | |
| 4-Androsten-3alpha,17alpha-diol monosulfate | Steroid | 0.68 | 0.47, 0.99 | 0.0445 | |
| 1-(1-Enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) | Plasmalogen | 1.49 | 1.06, 2.10 | 0.0229 | |
| 2-Hydroxyadipate | Fatty acid, dicarboxylate | 0.66 | 0.45, 0.96 | 0.028 | |
| 2-Stearoyl-GPE (18:0) | Lysolipid | 0.67 | 0.46, 0.97 | 0.0347 | |
|
Nucleotide |
0.73 | ||||
| Adenosine 3′,5′-cyclic monophosphate | Purine metabolism, adenine containing | 0.56 | 0.34, 0.92 | 0.0220 | |
|
Peptides |
0.29 | ||||
| Threonylphenylalanine | Dipeptide | 1.47 | 1.05, 2.06 | 0.0256 | |
| Gamma-glutamylphenylalanine | Gamma-glutamyl amino acid | 0.65 | 0.44, 0.96 | 0.0315 | |
| Gamma-glutamylglutamine | Gamma-glutamyl amino acid | 1.41 | 1.03, 1.94 | 0.0339 | |
|
Xenobiotics |
0.51 | ||||
| 1,3-Dimethylurate | Xanthine metabolism | 0.69 | 0.48, 0.99 | 0.0426 | |
Abbreviations: Alpha-CEHC=Alpha-carboxyethyl-hydroxychroman; CI=confidence interval; GPC=glycerophosphocholine; GPE=glycerophosphoethanolamine; OR=odds ratio.
a
The odds ratio per 80th percentile increase in metabolite. On the basis of 82 case–control pairs.
b
All metabolites had detectable values in >90% of the study population with the exception of alpha-CEHC glucuronide, alpha-CEHC sulfate, 1-palmitoyl-2-linolenoyl-GPC (16:0/18:3), 17alpha-hydroxypregnenolone sulfate, 2-hydroxyadipate, adenosine 3′,5′-cyclic monophosphate, and 1,3-dimethylurate (38%, 58%, 66%, 59%, 61%, 54% and 84%, respectively).